

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on May 28, 2026 | For discussion with your oncologist

TRIAL

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

NCT ID: NCT05607095 Phase: PHASE1 Sponsor: Memorial Sloan Kettering Cancer Center Status: Recruiting

SUMMARY

This is an open label study evaluating lifileucef (LN-144) in patients with metastatic uveal melanoma.

KEY ELIGIBILITY CRITERIA

- Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma.
- * Patients will be eligible regardless of the number of prior systemic therapies received.
- * Cohort 2: Must have a confirmed diagnosis of unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) that is refractory to at least 1 prior line of systemic therapy
- * Unresectable disease will be defined by an expert sarcoma surgical oncologist as either (a) low likelihood of obtaining an R0 resection or (b) unacceptable morbidity from a surgical procedure
- * Prior systemic therapy in the neoadjuvant or adjuvant setting will count as prior systemic therapy
- * Patients who refuse standard of care chemotherapy will be eligible
- * One (1) lesion at least 1.5cm in size (solitary or aggregate) available for TIL harvesting that has not undergone prior embolization or RT in prior 3 months unless subsequent growth is demonstrated (at least 0.5cm).
- * Patients must be ≥ 18 years of age at the time of consent.
- * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- * Patients must have an estimated life expectancy of ≥ 6 months in the opinion of the Investigator.

ENROLLMENT CONTACT

Alexander Shoushtari, MD

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Phone: 646-888-4161

Total sites: 2 | 2 currently recruiting